Cabozantinib S-Malate
FDA-approved product (capsule, oral), marketed as Cabometyx, Cabozantinib S-Malate, Cometriq.
- Registered studies
- 45
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Clear cell renal carcinoma
- Hepatocellular carcinoma
- Neoplasm
- Papillary renal cell carcinoma
- Papillary thyroid carcinoma
- Renal cell carcinoma
- Thyroid cancer
- Thyroid carcinoma
- Thyroid neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other protein kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
45registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cabozantinib S-Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
NCT04339738 · start 2020-11-04
Registered record
- Registry ID
- NCT04339738
- Conditions
- Skin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral Angiosarcoma
- Interventions
- Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; FDG-Positron Emission Tomography; Magnetic Resonance Imaging; Nivolumab; Paclitaxel; Quality-of-Life Assessment; Questionnaire Administration
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-11-04
- Completion
- 2027-01-21
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral AngiosarcomaInterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; FDG-Positron Emission Tomography +5 morePhasePhase 2Registry statusActive not recruitingTesting the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712 · start 2020-08-06
Registered record
- Registry ID
- NCT04079712
- Conditions
- Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
- Interventions
- Cabozantinib S-malate; Ipilimumab; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-08-06
- Completion
- 2026-08-19
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine CarcinomaInterventionCabozantinib S-malate; Ipilimumab; NivolumabPhasePhase 2Registry statusActive not recruitingTesting the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
NCT04071223 · start 2020-07-29
Registered record
- Registry ID
- NCT04071223
- Conditions
- Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Radium Ra 223 Dichloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-07-29
- Completion
- 2026-10-01
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma +5 moreInterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +4 morePhasePhase 2Registry statusActive not recruitingTesting the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007 · start 2020-07-13
Registered record
- Registry ID
- NCT04310007
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Docetaxel; Echocardiography Test; Gemcitabine Hydrochloride; Nab-paclitaxel; Nivolumab; Paclitaxel; Ramucirumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-07-13
- Completion
- 2026-12-31
- Enrolment
- 117
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Docetaxel +6 morePhasePhase 2Registry statusActive not recruitingCabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities
NCT04220229 · start 2020-06-01
Registered record
- Registry ID
- NCT04220229
- Conditions
- Sarcoma of the Extremity; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities; Stage II Soft Tissue Sarcoma of the Trunk and Extremities
- Interventions
- Cabozantinib S-malate; Radiation Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Terminated
- Start
- 2020-06-01
- Completion
- 2024-10-31
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcoma of the Extremity; Stage I Soft Tissue Sarcoma of the Trunk and Extremities; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities +1 moreInterventionCabozantinib S-malate; Radiation TherapyPhasePhase 1 / Phase 2Registry statusTerminatedTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT03914300 · start 2020-02-10
Registered record
- Registry ID
- NCT03914300
- Conditions
- Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma
- Interventions
- Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-02-10
- Completion
- 2026-12-17
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDifferentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma +5 moreInterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab +2 morePhasePhase 2Registry statusActive not recruitingCabozantinib in Advanced Adrenocortical Carcinoma
NCT03612232 · start 2019-06-04
Registered record
- Registry ID
- NCT03612232
- Conditions
- Adrenocortical Carcinoma
- Interventions
- Cabozantinib-s-malate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2019-06-04
- Completion
- 2025-04-30
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdrenocortical CarcinomaInterventionCabozantinib-s-malatePhasePhase 2Registry statusUnknownTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382 · start 2019-05-13
Registered record
- Registry ID
- NCT03866382
- Conditions
- Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2019-05-13
- Completion
- 2027-02-28
- Enrolment
- 314
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma +20 moreInterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +5 morePhasePhase 2Registry statusRecruitingTesting Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT03375320 · start 2018-10-26
Registered record
- Registry ID
- NCT03375320
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor
- Interventions
- Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2018-10-26
- Completion
- 2026-08-19
- Enrolment
- 298
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFunctioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1 +19 moreInterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging +3 morePhasePhase 3Registry statusActive not recruitingNivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
NCT03468985 · start 2018-05-07
Registered record
- Registry ID
- NCT03468985
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cabozantinib; Ipilimumab; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2018-05-07
- Completion
- 2022-12-21
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7InterventionCabozantinib; Ipilimumab; NivolumabPhasePhase 2Registry statusCompletedCabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
NCT03367741 · start 2018-04-16
Registered record
- Registry ID
- NCT03367741
- Conditions
- Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2018-04-16
- Completion
- 2027-07-23
- Enrolment
- 82
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 +1 moreInterventionBiopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +2 morePhasePhase 2Registry statusActive not recruitingCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592 · start 2017-05-18
Registered record
- Registry ID
- NCT02867592
- Conditions
- Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Ost
- Interventions
- Cabozantinib; Cabozantinib S-malate; Pharmacological Study
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2017-05-18
- Completion
- 2027-06-28
- Enrolment
- 109
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue +27 moreInterventionCabozantinib; Cabozantinib S-malate; Pharmacological StudyPhasePhase 2Registry statusActive not recruitingTesting Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
NCT02761057 · start 2016-07-25
Registered record
- Registry ID
- NCT02761057
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Crizotinib; Savolitinib; Sunitinib Malate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2016-07-25
- Completion
- 2023-10-19
- Enrolment
- 152
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLocally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 +3 moreInterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +3 morePhasePhase 2Registry statusCompletedEffect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
NCT02592356 · start 2015-11-16
Registered record
- Registry ID
- NCT02592356
- Conditions
- Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
- Interventions
- Computed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment; Questionnaire Administration; Cabozantinib; Lenvatinib
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2015-11-16
- Completion
- 2024-03-01
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDifferentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary CarcinomaInterventionComputed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment +3 morePhaseNot applicableRegistry statusCompletedCabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
NCT02496208 · start 2015-07-22
Registered record
- Registry ID
- NCT02496208
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2015-07-22
- Completion
- 2026-09-30
- Enrolment
- 152
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma +24 moreInterventionBiopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +4 morePhasePhase 1Registry statusActive not recruiting